In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections

Candida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available antifungals is limited, and antifungal-resistantCandida strains are emerging. New and effective antifungals are therefore urgently needed. Here, we discovered a small molecule with activity againstCandida spp. bothin vitro andin vivo.
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news